Slate Medicines to merge with Fulcrum in all-stock reverse merger, $245M concurrent PIPE

Cooley advised Slate Medicines on an all-stock reverse merger with Fulcrum Therapeutics, combining under the name Slate Medicines (Nasdaq: SLTE) and raising $245M via an oversubscribed private placement.